Cercar
01/07/2021
Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up
Diego, SG, Teresa, DD, Cores, C, Canfield, H, Paz Gonzalez, JM, Miro, CM, Aymerich, LV, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Hernandez-Vara, J, Cabo, I, Manzanares, LL, Aramburu, IG, Avila Rivera, MA, Catalan, MJ, Nogueira, V, Puente, V, Dotor, J, Borrue, C, Solano, B, Alvarez Sauco, M, Vela, L, Escalante, S, Cubo, E, Carrillo, F, Martinez Castrillo, JC, Alonso, PS, Alonso, G, Ariztegui, NL, Gaston, I, Kulisevsky, J, Blazquez, M, Seijo, M, Ruiz Martinez, J, Valero, C, Kurtis, M, de Fabregues, O, Ardura, J, Alonso, R, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P, COPPADIS Study Group. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine. 2021; 11(7)DOI:10.3390/jpm11070626. PMID:34209166. IF:3.508(Q2/4D).
01/11/2023
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021)
Dam, T, Golbe, LI, Hoglinger, GU, Grundman, M, Yang, LL, Tidemann-Miller, B, Kupferman, J, Harper, K, Kamisoglu, K, Wald, MJ, Graham, DL, Gedney, L, O'Gorman, J, Haeberlein, SB, Aiba, I, Antonini, A, Apetauerova, D, Azulay, JP, Martinez, EB, Bang, J, Barone, P, Barrett, M, Bega, D, Berg, D, Corrales, KB, Bordelon, Y, Boxer, AL, Brandt, M, Brueggemann, N, Castelnovo, G, Ceravolo, R, Chuang, RD, Chung, SJ, Church, A, Corvol, JC, Cudia, P, Dale, M, Defebvre, L, Drapier, S, Driver-Dunckley, ED, Ebersbach, G, Eggert, KM, Ellenbogen, A, Eusebio, A, Evans, AH, Fedorova, N, Finger, E, Foubert-Samier, A, Ghosh, B, Golbe, L, Perez, FG, Grossman, M, Hall, D, Hamada, K, Hasegawa, K, Hoeglinger, G, Honig, L, Houghton, D, Huang, XM, Isaacson, S, Koh, S, Bojarski, JK, Lang, ANE, Leigh, PN, Litvan, I, Lozano, JJL, Moreno, JLLS, Ludolph, AC, Piudo, MRL, Torres, IM, McFarland, N, Meissner, W, Mestre, T, Rivera, PM, Molho, E, Mollenhauer, B, Morris, HR, Murata, M, Obi, T, Magne, FO, O'Suilleabhain, P, Pahwa, R, Pantelyat, A, Pavese, N, Pokhabov, D, Prudlo, J, Rodriguez-Porcel, F, Rowe, J, Savitt, J, Schnitzler, A, Schulz, JB, Seppi, K, Shah, BI, Shill, H, Shprecher, D, Stamelou, M, Steiger, M, Takahashi, Y, Takigawa, H, Tartaglia, C, Toenges, L, Truong, D, Tse, W, Tuite, P, Volc, D, Wills, AMA, Woitalla, D, Xie, T, Yuasa, T, Zauber, SE, Zesiewicz, T. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021). NATURE MEDICINE. 2023; 29(11)DOI:10.1038/s41591-022-02076-8. PMID:36253611. IF:58.700(Q1/1D).
05/07/2023
Reduplicative paramnesia as an atypical form of presentation of a Heidenhain variant of Creutzfeldt-Jakob disease: A case report
Martinez-Horta, S, Marzal-Espi, CN, Cuso-Garcia, S, Aracil-Bolanos, I, Kulisevsky, J. Reduplicative paramnesia as an atypical form of presentation of a Heidenhain variant of Creutzfeldt-Jakob disease: A case report. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY. 2023; 29(6)DOI:10.1017/S1355617722000583. PMID:36062534. IF:2.600(Q2/4D).
01/03/2023
Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review
Rossi M., Hamed M., Rodríguez-Antigüedad J., Cornejo-Olivas M., Breza M., Lohmann K., Klein C., Rajalingam R., Marras C., van de Warrenburg B.P.. Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review. MOVEMENT DISORDERS. 2023; 38(3)DOI:10.1002/mds.29278. PMID:36374860. IF:7.400(Q1/1D).
01/01/2023
Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients
Gironell A., Pascual-Sedano B., Marín-Lahoz J., Pérez J., Pagonabarraga J.. Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients. Movement Disorders Clinical Practice. 2023; 10(1)DOI:10.1002/mdc3.13576. PMID:36704076. IF:2.600(Q2/5D).
01/01/2023
Autism Spectrum Disorder May Be Highly Prevalent in People with Functional Neurological Disorders
Gonzalez-Herrero, B, Morgante, F, Pagonabarraga, J, Stanton, B, Edwards, MJ. Autism Spectrum Disorder May Be Highly Prevalent in People with Functional Neurological Disorders. Journal of Clinical Medicine. 2023; 12(1)DOI:10.3390/jcm12010299. PMID:36615098. IF:3.000(Q1/2D).